An Educational Review of the Statistical Issues in Analysing Utility Data for Cost-Utility Analysis.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 4, p. 355, doi. 10.1007/s40273-014-0247-6
- By:
- Publication type:
- Article
Works matching IS 11707690 AND DT 2015 AND VI 33 AND IP 4
Results: 10
1
2
Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy.
- Published in:
- 2015
- By:
- Publication type:
- journal article
3
Economic Features of Antibiotic Resistance: The Case of Methicillin-Resistant Staphylococcus aureus.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 4, p. 285, doi. 10.1007/s40273-014-0242-y
- By:
- Publication type:
- Article
4
Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 4, p. 381, doi. 10.1007/s40273-014-0245-8
- By:
- Publication type:
- Article
5
Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 4, p. 327, doi. 10.1007/s40273-014-0244-9
- By:
- Publication type:
- Article
6
Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 4, p. 395, doi. 10.1007/s40273-014-0246-7
- By:
- Publication type:
- Article
7
Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective.
- Published in:
- 2015
- By:
- Publication type:
- journal article
8
Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilization-Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 4, p. 409, doi. 10.1007/s40273-014-0249-4
- By:
- Publication type:
- Article
9
Cost-of-Illness Studies for Bipolar Disorder: Systematic Review of International Studies.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 4, p. 341, doi. 10.1007/s40273-014-0250-y
- By:
- Publication type:
- Article
10
Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada.
- Published in:
- PharmacoEconomics, 2015, v. 33, n. 4, p. 367, doi. 10.1007/s40273-014-0241-z
- By:
- Publication type:
- Article